NCT00492076

Efficacy and Safety Trial of Subcutaneous Immunotherapy in Mite Induced Asthma

A Randomised, Double-Blind Placebo-Controlled Study Assessing the Short-Term Effect of a Dermatophagoides Pteronyssinus Extract, Quantified in Mass Units, in Subjects With Perennial Mite Induced Asthma

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: ALK-Abelló A/S · Industry
• Sex: All
• Age: 14 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether a short course of subcutaneous immunotherapy is efficacious in mite induced asthma. The efficacy is based on reduction in control medication.

Detailed description

The control of mild-moderate persistent asthma include the need of concomitant medication, as inhaled corticosteroids. However, compliance in perennial asthma is low. The aim of this study is to assess the possibility to reduce the need of concomitant medication through a short-course of subcutaneous immunotherapy.

Conditions

• Allergic Asthma

Interventions

Type	Name	Description
BIOLOGICAL	Pangramin Plus D. pteronyssinus 100%	1. Active. Pangramin Plus D. pteronyssinus 100% 2. Placebo. Pangramin Plus placebo

Timeline

• Start date: 2006-10-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2007-06-27
• Last updated: 2008-10-16

Locations

1 site across 1 country: Spain